Description
An inhibitor of JNK (IC50 = 280 nM); competitive for JNK1 binding with pepJIP1 (IC50 = 500 nM); selective for JNK over p38α, mTOR, and PI3Kα; inhibits c-Jun phosphorylation induced by TNF-α (EC50 = 12.4 µM); restores insulin sensitivity in a mouse model of type 2 diabetes when administered at 25 mg/kg 30 minutes prior to insulin; reduces human prostate strip contractions induced by phenylephrine or norepinephrine when applied at 30 µM and reduces phosphorylation of c-Jun, a JNK substrate,
Formal name: 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]-3H-1,2,4-triazol-3-one
Synonyms: c-Jun N-terminal Kinase Inhibitor X|JNK Inhibitor X
Molecular weight: 379.4
CAS: 883065-90-5
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|JNK||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cell Biology|Cell Signaling||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes
